Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest & Investment Income: 2020-2025

Historic Interest & Investment Income for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $4.1 million.

  • Tarsus Pharmaceuticals' Interest & Investment Income fell 0.15% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 7.66%. This contributed to the annual value of $15.0 million for FY2024, which is 45.25% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Interest & Investment Income stood at $4.1 million for Q3 2025, which was down 2.72% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Interest & Investment Income ranged from a high of $4.2 million in Q2 2025 and a low of $7,000 during Q2 2021.
  • For the 3-year period, Tarsus Pharmaceuticals' Interest & Investment Income averaged around $3.4 million, with its median value being $3.5 million (2025).
  • In the last 5 years, Tarsus Pharmaceuticals' Interest & Investment Income crashed by 94.41% in 2021 and then spiked by 17,625.00% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $12,000 in 2021, then skyrocketed by 17,625.00% to $2.1 million in 2022, then surged by 40.01% to $3.0 million in 2023, then climbed by 22.46% to $3.6 million in 2024, then declined by 0.15% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $4.2 million for Q2 2025, and $3.5 million during Q1 2025.